If gene variants coding for CYP3A4/5, the mitochondrial enzyme GATM, the influx transporter OATP1B1 (encoded by SLCO1B1), and the efflux transporters P-gp (encoded by ABCB1) have a theoretical potential for affecting absorption, distribution, metabolism, and excretion of statins, only the ∗5 allele of SLCO1B1 has been strongly identified to be clinically associated with statin induced myopathy, especially for simvastatin [14, 15]. This evidence concerns the gene CYP3A4 and myopathy.